• DiscoveryProbe Bioactive Compound Library Plus: Assay Powerh

  2026-04-30

  Leverage the DiscoveryProbe Bioactive Compound Library Plus to supercharge high-throughput screening and mechanistic pathway analysis. This rigorously validated library enables precise, reproducible workflows in cancer, immunology, and signal transduction research—empowering scientists to troubleshoot and optimize assays with confidence.

• Doxorubicin Hydrochloride in Cancer and Cardiotoxicity Model

  2026-04-30

  Doxorubicin hydrochloride (Adriamycin HCl) is a cornerstone of cancer chemotherapy research, uniquely enabling high-fidelity DNA damage, apoptosis, and cardiotoxicity modeling. Recent mechanistic advances, such as ATF4-mediated cardioprotection, offer new avenues for assay design and translational insight. This guide delivers actionable workflow parameters, troubleshooting expertise, and direct links to the latest evidence and resource integration.

• Assembly Mechanisms of the Multipass ER Translocon Revealed

  2026-04-29

  This study defines how the endoplasmic reticulum (ER) forms a specialized translocon complex for multipass membrane protein biogenesis. By dissecting the dynamic recruitment of distinct protein complexes to the Sec61 core, the research reveals substrate-driven assembly processes that ensure the fidelity and efficiency of multipass protein integration.

• Doxorubicin as a Chemotherapeutic Benchmark: Pathways, Proto

  2026-04-29

  Explore the multifaceted role of Doxorubicin (Adriamycin) as a DNA topoisomerase II inhibitor and apoptosis inducer in cancer research. This article uniquely bridges mechanistic depth with protocol precision and practical benchmarking, providing researchers with evidence-based guidance for advanced applications in solid tumor and hematologic malignancy models.

• Peripheral Endosome Entrapment Limits LNP Trafficking and Es

  2026-04-28

  This study dissects how lipid nanoparticles (LNPs) become entrapped in peripheral endosomes, impeding their intracellular trafficking and cytosolic release, whereas lysosomal accumulation supports effective transgene expression. These insights clarify key bottlenecks in nucleic acid delivery and inform strategies to optimize LNP-mediated RNA therapeutics.

• SCH772984 HCl: Precision ERK1/2 Inhibitor for Translational

  2026-04-28

  SCH772984 HCl delivers nanomolar ERK1/2 inhibition, enabling robust dissection of MAPK signaling and resistance in BRAF- and RAS-mutant cancers. This guide details applied workflows, protocol optimization, and troubleshooting for advanced cancer and stem cell research leveraging this selective inhibitor.

• TSPAN18 Protects STIM1 to Drive Bone Metastasis in Prostate

  2026-04-27

  Zhou et al. (2023) identify TSPAN18 as a key regulator that promotes bone metastasis in prostate cancer by protecting STIM1 from TRIM32-mediated ubiquitination, thereby enhancing store-operated calcium entry (SOCE) and metastatic potential. This study clarifies a previously uncharacterized mechanism in calcium signaling linked to poor prognosis, supporting new directions for targeted research and therapeutic intervention.

• Strategic Advances in mCherry mRNA: Stability, Immune Evasio

  2026-04-27

  This thought-leadership article explores how EZ Cap™ mCherry mRNA (5mCTP, ψUTP) from APExBIO redefines the landscape for reporter gene mRNA applications by integrating mechanistic innovation, translational guidance, and evidence-backed insight. We bridge foundational biology with strategic protocol recommendations, contextualize recent advances in mRNA delivery, and map a forward-looking vision for translational researchers seeking robust, immune-evasive fluorescent protein expression.

• Targeting PERK: New Horizons in ER Stress and Pyroptosis Res

  2026-04-26

  This thought-leadership article explores the mechanistic and translational significance of GSK2606414, a potent and selective PERK inhibitor, in dissecting ER stress-driven pyroptosis. Drawing on recent research into the PERK/eIF2α/ATF4–JAK1–STAT3 axis in intervertebral disc degeneration, it provides actionable guidance for translational scientists, evidentiary protocol recommendations, and a strategic outlook on therapeutic innovation.

• MTT Assay Reimagined: Precision Tools for Translational Rese

  2026-04-25

  This thought-leadership article explores how MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) has evolved from a routine cell viability assay reagent to a mechanistically precise, strategically indispensable tool for translational researchers. By weaving together biochemical insight, competitive benchmarking, and critical findings from multidrug resistance studies, the article offers actionable guidance for enhancing rigor and translational value in preclinical pipelines. APExBIO’s high-purity MTT (SKU: B7777) is contextualized as a gold-standard choice for robust, reproducible metabolic activity measurement, with protocol parameters and outlook grounded in the latest evidence.

• Obacunone Regulates Ferroptosis in Ovarian Cancer via Akt/p5

  2026-04-24

  This study uncovers how Obacunone, a citrus-derived compound, induces ferroptosis in ovarian cancer cells by modulating the Akt/p53 signaling axis. The findings highlight a mechanistic link between Akt inactivation and ferroptotic cell death, offering new directions for targeted cancer research.

• Dual-Action Kinase Inhibitors Modulate p38α MAPK Dephosphory

  2026-04-24

  The reference study reveals that certain kinase inhibitors can both block p38α MAPK activity and accelerate its dephosphorylation by phosphatases, introducing a dual-action mechanism with implications for inhibitor specificity and potency. Structural insights from X-ray crystallography demonstrate how inhibitor-induced conformational changes increase phosphatase accessibility, suggesting a new paradigm for therapeutic kinase inhibitor design.

• Doxorubicin Hydrochloride: Mechanism, Benchmarks & Research

  2026-04-23

  Doxorubicin hydrochloride (Adriamycin HCl) is a validated anthracycline antibiotic and DNA topoisomerase II inhibitor, foundational in cancer chemotherapy research. It exhibits cytotoxic effects at low micromolar concentrations and serves as a robust model for apoptosis and cardiotoxicity studies. This article details the mechanistic, experimental, and workflow parameters for confidently integrating Doxorubicin HCl into preclinical research.

• Fulvestrant (ICI 182,780): Mechanism, Evidence, and Research

  2026-04-23

  Fulvestrant (ICI 182,780) is a potent estrogen receptor antagonist used in advanced breast cancer research. It downregulates ER signaling, induces MDM2 protein degradation, and sensitizes ER-positive breast cancer cells to chemotherapy. Its mechanism, benchmarks, and optimal use protocols are detailed here.

• Plk1 Regulation of p31comet in Mitotic Checkpoint Disassembl

  2026-04-22

  This study elucidates the mechanistic control of mitotic checkpoint inactivation by demonstrating that Polo-like kinase 1 (Plk1) phosphorylates p31comet, thereby inhibiting its role in disassembling mitotic checkpoint complexes (MCC). The work advances understanding of spindle assembly checkpoint fidelity and proposes new regulatory layers in cell cycle progression.

15037 records 1/1003 page Next 12345 下5页 Last page